Abaloparatide effects on BMD in acetabular regions corresponding to DeLee and Charnley zones in women with postmenopausal osteoporosis

IF 2.6 Q3 ENDOCRINOLOGY & METABOLISM

Bone Reports Pub Date : 2025-07-19 DOI:10.1016/j.bonr.2025.101858

Neil P. Sheth , Kelly Krohn , Jared Torkelson , Renaud Winzenrieth , Ludovic Humbert , Leny Pearman , Yamei Wang , John I. Boxberger , Mathias P. Bostrom

{"title":"Abaloparatide effects on BMD in acetabular regions corresponding to DeLee and Charnley zones in women with postmenopausal osteoporosis","authors":"Neil P. Sheth , Kelly Krohn , Jared Torkelson , Renaud Winzenrieth , Ludovic Humbert , Leny Pearman , Yamei Wang , John I. Boxberger , Mathias P. Bostrom","doi":"10.1016/j.bonr.2025.101858","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Acetabular bone loss in patients with osteoporosis is associated with increased risk of acetabular fragility fractures, significant morbidity, and can increase risk of complications in patients undergoing total hip arthroplasty. The anabolic osteoporosis treatment abaloparatide increases total hip areal bone mineral density (BMD), but its effect on acetabular BMD is unknown.</div></div><div><h3>Methods</h3><div>Anatomical landmarks were identified in DXA scans from a random subgroup of postmenopausal women with osteoporosis (PMO) treated with abaloparatide 80 μg/d or placebo (n = 250/group) from the phase 3 ACTIVE trial to virtually place a hemispherical shell model of an acetabular cup and define regions of interest corresponding to DeLee and Charnley zones 1 (R1), 2 (R2), and 3 (R3). Changes in BMD from baseline at 6 and 18 months were calculated. Statistical significance was tested using a mixed model with repeated measures. Local mean changes in BMD were depicted by alignment of DXA scans via intensity-based registration onto a reference scan.</div></div><div><h3>Results</h3><div>Abaloparatide significantly increased acetabular areal BMD in all three DeLee and Charnley zones at 6 and 18 months versus placebo. Mean BMD increases with abaloparatide were 8.38 % (R1), 7.25 % (R2), and 9.73 % (R3) at 18 months. BMD increases were homogenously distributed throughout the regions. With placebo, localized losses in BMD were noted after 18 months.</div></div><div><h3>Conclusions</h3><div>Abaloparatide treatment rapidly and progressively increases BMD in acetabular zones in PMO.</div></div><div><h3>Clinical trial number</h3><div><span><span>NCT01343004</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"26 ","pages":"Article 101858"},"PeriodicalIF":2.6000,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S235218722500035X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Acetabular bone loss in patients with osteoporosis is associated with increased risk of acetabular fragility fractures, significant morbidity, and can increase risk of complications in patients undergoing total hip arthroplasty. The anabolic osteoporosis treatment abaloparatide increases total hip areal bone mineral density (BMD), but its effect on acetabular BMD is unknown.

Methods

Anatomical landmarks were identified in DXA scans from a random subgroup of postmenopausal women with osteoporosis (PMO) treated with abaloparatide 80 μg/d or placebo (n = 250/group) from the phase 3 ACTIVE trial to virtually place a hemispherical shell model of an acetabular cup and define regions of interest corresponding to DeLee and Charnley zones 1 (R1), 2 (R2), and 3 (R3). Changes in BMD from baseline at 6 and 18 months were calculated. Statistical significance was tested using a mixed model with repeated measures. Local mean changes in BMD were depicted by alignment of DXA scans via intensity-based registration onto a reference scan.

Results

Abaloparatide significantly increased acetabular areal BMD in all three DeLee and Charnley zones at 6 and 18 months versus placebo. Mean BMD increases with abaloparatide were 8.38 % (R1), 7.25 % (R2), and 9.73 % (R3) at 18 months. BMD increases were homogenously distributed throughout the regions. With placebo, localized losses in BMD were noted after 18 months.

Conclusions

Abaloparatide treatment rapidly and progressively increases BMD in acetabular zones in PMO.

Clinical trial number

NCT01343004.

Abstract Image

查看原文本刊更多论文

阿巴巴肽对绝经后骨质疏松症妇女髋臼区DeLee和Charnley区骨密度的影响

背景：骨质疏松患者髋臼骨丢失与髋臼脆性骨折的风险增加、发病率显著相关，并可增加全髋关节置换术患者的并发症风险。合成代谢骨质疏松治疗阿巴巴拉肽可增加髋部总骨密度（BMD），但对髋臼骨密度的影响尚不清楚。方法对绝经后骨质疏松症（PMO）妇女随机亚组进行DXA扫描，该亚组接受阿巴帕肽80 μg/d或安慰剂（n = 250/组）治疗，从3期ACTIVE试验中放置一个半球形髋臼杯模型，并确定与DeLee和Charnley区1 (R1), 2 （R2）和3 （R3）相对应的兴趣区域。计算6个月和18个月时骨密度与基线的变化。采用重复测量的混合模型检验统计显著性。通过基于强度的配准与参考扫描的DXA扫描对齐来描述BMD的局部平均变化。结果与安慰剂相比，巴洛帕肽在6个月和18个月时显著增加了所有三个DeLee和Charnley区的髋臼面积骨密度。18个月时，阿巴巴拉肽的平均骨密度增加率分别为8.38% （R1）、7.25% （R2）和9.73% （R3）。骨密度增加在各区域均匀分布。使用安慰剂，18个月后发现局部骨密度下降。结论巴洛帕肽治疗可迅速、渐进地提高PMO患者髋臼区的骨密度。临床试验编号：bernct01343004。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bone Reports Medicine-Orthopedics and Sports Medicine

CiteScore

4.30

自引率

4.00%

发文量

444

审稿时长

57 days

期刊介绍： Bone Reports is an interdisciplinary forum for the rapid publication of Original Research Articles and Case Reports across basic, translational and clinical aspects of bone and mineral metabolism. The journal publishes papers that are scientifically sound, with the peer review process focused principally on verifying sound methodologies, and correct data analysis and interpretation. We welcome studies either replicating or failing to replicate a previous study, and null findings. We fulfil a critical and current need to enhance research by publishing reproducibility studies and null findings.